Intouch Solutions proudly announces the promotions of both Vicky Cory and Krisha Newham to vice president of client services.
For patients with deadly and debilitating conditions, FDA drug approvals can be cause for celebration. Many of these patients and their families have been waiting years for better therapies – or any therapy at all. They consume every public announcement about drug approvals for their particular disease like it’s water in the desert. But there is also a sense of trepidation once the drug launches. How much will this new drug cost? What will insurance cover? What will be our share?
The Carlyle Group and GTCR LLC are acquiring contract research organization Albany Molecular Research (AMRI) for about $922 million in cash.
The World Health Organization published a new classification of antibiotics that aims to fight drug resistance, with penicillin-type drugs recommended as the first line of defense and others only for use when absolutely necessary.
A new study of physicians and health plan executives reveals some progress toward achieving value-based care, but indicates health information technology, such as electronic health records (EHRs) are still not bridging many critical gaps.
Shares of Acorda Therapeutics were up as the company moves closer to securing regulatory approval for its inhaled Parkinson’s disease treatment, CVT-301.
Seattle’s City Council voted to levy a special tax on sodas and other sugary beverages sold to consumers, becoming the latest of several local government bodies across the country to take such action for the sake of public health.
Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industry, announced the ambr 15 automated micro bioreactor system combined with a Nova Biomedical BioProfile FLEX2 automated cell culture analyzer.
FDA approved Edwards Lifesciences’ Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.